Combination therapy for unremovable bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments for people with bile duct or gallbladder cancer that cannot be removed by surgery. It uses a procedure to burn the tumor (radiofrequency ablation) along with two drugs: one that boosts your immune system and one that targets blood vessels feeding the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must have a confirmed diagnosis of bile duct or gallbladder cancer that cannot be removed by surgery.
- You haven't had any previous treatment for this cancer, and you are not able to have or don't want chemotherapy.
- Your tumor can be seen on a CT scan, with a size of at least about 1 cm for the main tumor or 1.5 cm for lymph nodes.
- You need to be in good general health, with blood counts, liver, and kidney function within safe limits.
- You must not have other serious medical conditions like active infections, heart problems, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial tests a combination of surufatinib (a targeted drug) plus immunotherapy and chemotherapy for people with bile duct or gallbladder cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of four treatments for people with bile duct cancer that cannot be removed by surgery. The treatments include chemotherapy directly into the liver, tiny beads with chemo, an immunotherapy drug, and a targeted therapy pill. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (surufatinib and toripalimab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can shrink tumors or slow the cancer.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Unresectable Biliary Tract Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.